{"title": "Formulation and Delivery Technologies for mRNA Vaccines", "chroma:document": "Kallen K-J, Heidenreich R, Schnee M et al (2013) A novel, disruptive vaccination technology:\nself-adjuvanted RNActive(\u00ae) vaccines. Human vaccines & immunotherapeutics 9:2263 \u20132276\nKang Z, Meng Q, Liu K (2019) Peptide-based gene delivery vectors. Journal of Materials\nChemistry B 7:1824 \u20131841\nKariko K, Buckstein M, Ni H et al (2005) Suppression of RNA recognition by Toll-like receptors: the\nimpact of nucleoside modi \ufb01cation and the evolutionary origin of RNA. Immunity 23:165 \u2013175\nKarik \u00f3K, Muramatsu H, Ludwig J et al (2011) Generating the optimal mRNA for therapy: HPLC\npuri\ufb01cation eliminates immune activation and improves translation of nucleoside-modi \ufb01ed,\nprotein-encoding mRNA. Nucleic Acids Res 39:e142 \u2013e42\nKariko K, Muramatsu H, Welsh FA et al (2008) Incorporation of pseudouridine into mRNA yields\nsuperior nonimmunogenic vector with increased translational capacity and biological stability.Mol Ther 16:1833 \u20131840\nKashem SW, Haniffa M, Kaplan DH (2017) Antigen-presenting cells in the skin. Annu Rev\nImmunol 35:469 \u2013499\nKong N, Tao W, Ling X et al (2019) Synthetic mRNA nanoparticle-mediated restoration of p53\ntumor suppressor sensitizes <em> p53 </em>-de \ufb01cient cancers to mTOR inhibition. Sci Transl\nMed 11: eaaw1565\nKose N, Fox JM, Sapparapu G et al (2019) A lipid-encapsulated mRNA encoding a potently\nneutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol\n4:eaaw6647\nKowalski PS, Rudra A, Miao L et al (2019) Delivering the messenger: advances in technologies\nfor therapeutic mRNA delivery. Mol Ther\nKranz LM, Diken M, Haas H et al (2016) Systemic RNA delivery to dendritic cells exploits\nantiviral defence for cancer immunotherapy. Nature 534:396\nKreiter S, Selmi A, Diken M et al (2010) Intranodal vaccination with naked antigen-encoding\nRNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70:9031 \u2013\n9040\nKubler H, Scheel B, Gnad-Vogt U et al (2015) Self-adjuvanted mRNA vaccination in advanced\nprostate cancer patients: a \ufb01rst-in-man phase I/IIa study. J Immunother Cancer 3:26\nLeal L, Guardo AC, Mor \u00f3n-L\u00f3pez S et al (2018) Phase I clinical trial of an intranodally\nadministered mRNA-based therapeutic vaccine against HIV-1 infection. AIDS 32:2533 \u20132545\nLee JA (1981) Sydney Ringer (1834-1910) and Alexis Hartmann (1898-1964). Anaesthesia\n36:1115 \u20131121\nLi B, Zhang X, Dong Y (2019) Nanoscale platforms for messenger RNA delivery. Wiley Interdisc\nRev Nanomed Nanobiotechnol 11:e1530\nLi W, Joshi MD, Singhania S et al (2014) Peptide vaccine: progress and challenges. Vaccines\n2:515 \u2013536\nLi M, Li Y, Peng K et al (2017a) Engineering intranasal mRNA vaccines to enhance lymph node\ntraf\ufb01cking and immune responses. Acta Biomater 64:237 \u2013248\nLi W, Ma L, Guo L-P et al (2017b) West Nile virus infectious replicon particles generated using a\npackaging-restricted cell line is a safe reporter system. Sci Rep 7:3286\nLiang F, Lindgren G, Lin A et al (2017) Ef \ufb01cient targeting and activation of antigen-presenting\ncells in vivo after modi \ufb01ed mRNA vaccine administration in rhesus macaques. Mol Ther\n25:2635 \u20132647\nLim JP, Gleeson PA (2011) Macropinocytosis: an endocytic pathway for internalising large gulps.\nImmunol Cell Biol 89:836 \u2013843\nLindsay KE, Bhosle SM, Zurla C et al (2019) Visualization of early events in mRNA vaccine\ndelivery in non-human primates via PET \u2013CT and near-infrared imaging. Nat Biomed Eng\n3:371 \u2013380\nLindsay KE, Vanover D, Thoresen M et al (2020) Aerosol delivery of synthetic mRNA to vaginal\nmucosa leads to durable expression of broadly neutralizing antibodies against HIV. Mol Ther\n28:805 \u2013819\nLiu C, Feng Q, Sun J (2018) Lipid nanovesicles by micro \ufb02uidics: manipulation, synthesis, and\ndrug delivery. Adv